Understanding the Molecular Basis of Fragile X Syndrome Using Differentiated Mesenchymal Stem Cells
Iranian Journal of Child Neurology,
Vol. 16 No. 1 (2022),
Fragile X syndrome (FXS) has been known as the most common cause of inherited intellectual disability and autism. This disease results from the loss of fragile X mental retardation protein expression due to the expansion of CGG repeats located on the 5’ untranslated region of the fragile X mental retardation 1 (FMR1) gene.
Materials & Methods
In the present study, the peripheral blood-mesenchymal stem cells (PB-MSCs) of two female full mutation carriers were differentiated into neuronal cells by the suppression of bone morphogenesis pathway
signaling. Then, the expression of genes adjacent to CGG repeats expansion, including SLIT and NTRK-like protein 2 (SLITRK2), SLIT and NTRK-like protein 4 (SLITRK4), methyl CpG binding protein 2 (MECP2), and gamma-aminobutyric acid receptor subunit alpha-3 (GABRA3), were evaluated in these cells using SYBR Green real-time polymerase chain reaction.
The obtained results indicated that the expression of SLITRK2 and SLITRK4 were upregulated and downregulated in the neuron-like cells differentiated from the PB-MSCs of females with FMR1 full mutation, compared to that of the normal females, respectively. Furthermore, the expression of MECP2 and GABRA3 genes were observed to be related to the phenotypic differences observed in the female FMR1
full mutation carriers
The observed association of expression of genes located upstream of the FMR1 gene with phenotypic differences in the female carriers could increase the understanding of novel therapeutic targets for patients with mild symptoms of FXS and the patients affected by other FMR1-related disorders
- Fragile X syndrome
- Molecular Mechanism
- Mesenchymal stem cells
How to Cite
- Martyn M, Anderson V, Archibald A, Carter R, Cohen J, Delatycki M, et al. Offering fragile X syndrome carrier screening: a prospective mixed-methods observational study comparing carrier screening of pregnant and non-pregnant women in the general population. BMJ Open. 2013;3(9): e003660.
- Crawford DC, Acuña JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med. 2001; 3(5):359-71.
- Hatton DD, Sideris J, Skinner M, Mankowski J, Bailey DB Jr, Roberts J, et al. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A. 2006;140 A(17):1804-13.
- Moss J, Howlin P. Autism spectrum disorders in genetic syndromes: implications for diagnosis, intervention and understanding the wider autism spectrum disorder population. J Intellect Disabil Res. 2009;53(10):852-73.
- Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med. 2005;7(8):584-7.
- de Vries BB, Wiegers AM, Smits AP, Mohkamsing S, Duivenvoorden HJ, Fryns JP, et al. Mental status of females with an FMR1 gene full mutation. Am J Hum Genet. 1996;58(5):1025-32.
- Munir F, Cornish KM, Wilding J. Nature of the working memory deficit in fragile-X syndrome. Brain Cogn. 2000;44(3):387-401.
- Wilding J, Cornish K, Munir F. Further delineation of the executive deficit in males with fragile-X syndrome. Neuropsychologia. 2002;40(8):1343-9.
- Cornish KM, Munir F, Cross G. Spatial cognition in males with Fragile-X syndrome: evidence for a neuropsychological phenotype. Cortex. 1999;35(2):263-71.
- Hall SS, Burns DD, Lightbody AA, Reiss AL. Longitudinal changes in intellectual development in children with Fragile X syndrome. J Abnorm Child Psychol. 2008;36(6):927-39.
- Brouwer JR, Mientjes EJ, Bakker CE, Nieuwenhuizen IM, Severijnen LA, Van der Linde HC, et al. Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation. Exp Cell Res. 2007;313(2):244-53.
- Tyson JA, Anderson SA. The protracted maturation of human ESC-derived interneurons. Cell Cycle. 2013;12(19):3129-30.
- Marín O. Human cortical interneurons take their time. Cell Stem Cell. 2013;12(5):497-9.
- Gerhardt J. Epigenetic modifications in human fragile X pluripotent stem cells; Implications in fragile X syndrome modeling. Brain Res. 2015: 1656:55‐62.
- Kim S, Honmou O, Kato K, Nonaka T, Houkin K, Hamada H, et al. Neural differentiation potential of peripheral blood- and bone-marrow-derived precursor cells. Brain Res. 2006;1123(1):27-33.
- Weiler IJ, Greenough WT. Synaptic synthesis of the Fragile X protein: possible involvement in synapse maturation and elimination. Am J Med Genet. 1999;83(4):248-52.
- Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, Miyashiro K, et al. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci U S A. 1997;94(10):5395-400.
- Darnell JC, Richter JD. Cytoplasmic RNA-binding proteins and the control of complex brain function. Cold Spring Harb Perspect Biol. 2012;4(8): a012344.
- Bittel DC, Kibiryeva N, Butler MG. Whole genome microarray analysis of gene expression in subjects with fragile X syndrome. Genet Med. 2007; 9(7):464-72.
- Zhou Y, Lum JM, Yeo GH, Kiing J, Tay SK, Chong SS. Simplified molecular diagnosis of fragile X syndrome by fluorescent methylation-specific PCR and GeneScan analysis. Clin Chem. 2006;52(8):1492-500.
Marteyn A, Maury Y, Gauthier MM, Lecuyer C, Vernet R, Denis JA, et al. Mutant human embryonic stem cells reveal neurite and synapse formation defects in type 1 myotonic dystrophy. Cell Stem Cell. 2011;8(4):434-44
- Squillaro T, Alessio N, Cipollaro M, Melone MA, Hayek G, Renieri A, et al. Reduced expression of MECP2 affects cell commitment and maintenance in neurons by triggering senescence: new perspective for Rett syndrome. Mol Biol Cell. 2012;23(8):1435-45.
- Plummer PN, Colson NJ, Lewohl JM, MacKay RK, Fernandez F, Haupt LM, et al. Significant differences in gene expression of GABA receptors in peripheral blood leukocytes of migraineurs. Gene. 2011;490(1-2):32-6.
- Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9): e45.
- Castrén ML, Castrén E. BDNF in fragile X syndrome. Neuropharmacology. 2014 Jan;76 Pt C:729-36.
- Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2009;123(1):378-90.
- Healy A, Rush R, Ocain T. Fragile X syndrome: an update on developing treatment modalities. ACS Chem Neurosci. 2011;2(8):402-10.
- Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991;66(4):817-22.
- Stöger R, Genereux DP, Hagerman RJ, Hagerman PJ, Tassone F, Laird CD. Testing the FMR1 promoter for mosaicism in DNA methylation among CpG sites, strands, and cells in FMR1-expressing males with fragile X syndrome. PLoS One. 2011;6(8): e23648.
- Tassone F, Hagerman RJ, Taylor AK, Hagerman PJ. A majority of fragile X males with methylated, full mutation alleles have significant levels of FMR1 messenger RNA. J Med Genet. 2001;38(7):453-6.
- Aruga J, Mikoshiba K. Identification and characterization of Slitrk, a novel neuronal transmembrane protein family controlling neurite outgrowth. Mol Cell Neurosci. 2003; 24(1):117-29.
- Yim YS, Kwon Y, Nam J, Yoon HI, Lee K, Kim DG, et al. Slitrks control excitatory and inhibitory synapse formation with LAR receptor protein tyrosine phosphatases. Proc Natl Acad Sci U S A. 2013;110(10):4057-62.
- Smith EN, Bloss CS, Badner JA, Barrett T, Belmonte PL, Berrettini W, et al. Genome-wide association study of bipolar disorder in European American and African American individuals. Mol Psychiatry. 2009; 14(8):755-63.
- Moretti P, Levenson JM, Battaglia F, Atkinson R, Teague R, Antalffy B, et al. Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. J Neurosci. 2006;26(1):319-27.
- Dani VS, Nelson SB. Intact long-term potentiation but reduced connectivity between neocortical layer 5 pyramidal neurons in a mouse model of Rett syndrome. J Neurosci. 2009; 29(36):11263-70.
- Collins AL, Levenson JM, Vilaythong AP, Richman R, Armstrong DL, Noebels JL, et al. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet. 2004;13(21):2679-89.
- Gonzales ML, LaSalle JM. The role of MeCP2 in brain development and neurodevelopmental disorders. Curr Psychiatry Rep. 2010;12(2):127-34.
- D'Hulst C, De Geest N, Reeve SP, Van Dam D, De Deyn PP, Hassan BA, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 2006;1121(1):238-45.
- D'Hulst C, Heulens I, Brouwer JR, Willemsen R, De Geest N, Reeve SP, et al. Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res. 2009; 1253:176-83.
- Fatemi SH, Reutiman TJ, Folsom TD, Rustan OG, Rooney RJ, Thuras PD. Downregulation of GABAA receptor protein subunits α6, β2, δ, ε, γ2, θ, and ρ2 in superior frontal cortex of subjects with autism. J Autism Dev Disord. 2014;44(8):1833-45.
- Mihalek RM, Banerjee PK, Korpi ER, Quinlan JJ, Firestone LL, Mi ZP, et al. Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout mice. Proc Natl Acad Sci U S A. 1999;96(22):12905-10.
- Takayama C, Inoue Y. Transient expression of GABAA receptor alpha2 and alpha3 subunits in differentiating cerebellar neurons. Brain Res Dev Brain Res. 2004;148(2):169-77.
Geracitano R, Fischer D, Kasugai Y, Ferraguti F, Capogna M. Functional expression of the GABA(A) receptor α2 and α3 subunits at synapses between intercalated medial paracapsular neurons of mouse amygdala. Front Neural Circuits. 2012; 6:32
- Abstract Viewed: 609 times
- pdf Downloaded: 0 times